![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Callisto Announces Details of Upcoming Trial of Annamycin
Callisto Announces Details of Upcoming Trial of Annamycin
May 20, 2005
Callisto Pharmaceuticals has announced further details of its planned trial of Annamycin in adults with relapsed/refractory acute lymphoblastic leukemia (ALL) patients planned to begin in mid-2005.
The earlier Phase I trial of Annamycin performed in acute leukemia patients by a prior sponsor was recently subjected to a careful audit by Callisto of efficacy and safety data.
Based on this review, the company plans to include in the next trial with Annamycin in adult relapsed/refractory ALL patients an initial evaluation of a small number of patients (two cohorts totaling approximately six patients) to reconfirm the initial safety data in a Phase I/IIa trial that will then be rolled into a larger Phase IIb trial.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct